Clinical trials
Active, not recruiting trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,683 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 25 |
| 2016 | 23 |
| 2017 | 40 |
| 2018 | 64 |
| 2019 | 95 |
| 2020 | 153 |
| 2021 | 241 |
| 2022 | 328 |
| 2023 | 392 |
| 2024 | 543 |
| 2025 | 538 |
| 2026 | 211 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 2,683 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 103 |
| Sun Yat-sen University | 78 |
| Novartis Pharmaceuticals | 64 |
| Fudan University | 54 |
| Hoffmann-La Roche | 53 |
| Janssen Research & Development, LLC | 43 |
| Merck Sharp & Dohme LLC | 40 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 37 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 36 |
| Eli Lilly and Company | 30 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 184 |
| Breast Neoplasms | 136 |
| Colorectal Neoplasms | 61 |
| Stomach Neoplasms | 54 |
| Neoplasms | 52 |
| Obesity | 50 |
| Carcinoma, Hepatocellular | 46 |
| Prostatic Neoplasms | 40 |
| Lung Neoplasms | 39 |
| Nasopharyngeal Carcinoma | 39 |
Trials
Showing 76 to 100 of 2,683. Each trial links to its page on Pharma Observatory.
2,583 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.